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Prothrombotic fibrin clot phenotype, involving faster formation of dense meshwork composed of thinner and highly branched
fibers that are relatively resistant to plasmin-induced lysis, has been reported in patients with not only myocardial infarction
or stroke, but also venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT), and/or pulmonary embolism
(PE). Prothrombotic fibrin clot phenotype, in particular prolonged clot lysis time, is considered a novel risk factor for VTE as
well as venous thrombosis at unusual location, for example, cerebral sinus venous thrombosis, retinal vein obstruction, and Budd-
Chiari syndrome. Growing evidence from observational studies indicates that abnormal fibrin clot properties can predict recurrent
DVT and PE and they are involved in serious complications of VTE, for example, thromboembolic pulmonary hypertension and
postthrombotic syndrome.The purpose of this article is to review our current understanding of the role of fibrin clot structure and
function in venous thrombosis with emphasis on clinical issues ranging from prognosis to therapy.
1. Introduction
Fibrinogen is converted to fibrin by thrombin [1, 2].
Thrombin-mediated release of fibrinopeptide A (FPA) and
FPB from the N-termini of the A𝛼- and B𝛽-chains, respec-
tively, results in the formation of fibrin monomer (𝛼, 𝛽, 𝛾)
2
.
At the first stage of polymerization of fibrin monomers half-
staggered and double-stranded protofibrils are formed sup-
ported by “A:a” interactions and then there is the assembly
of protofibrils into fibers that are composed of thousands
of protofibrils arranged side-by-side. Lateral aggregation is
associated with FPB release and is likely caused by release
of the C-termini of the A𝛼-chains which interact and
form bridges between protofibrils. Lateral aggregation is
promoted mainly not only by intermolecular 𝛼C:𝛼C interac-
tions between protofibrils, but also probably by interactions
between both 𝛼- and 𝛾-chains [1, 2].
Formation of covalent cross-links formed by activated
factor (F)XIII improves elasticity of fibrin clots and resistance
to enzymatic degradation [3]. Dissolution of a fibrin clot is
mediated by the interaction of tissue plasminogen activator
(tPA) and plasminogen on fibrin fibers, which enhances
the conversion of plasminogen to plasmin by tPA. Plasmin
cleaves Lys-X and Arg-X bonds in the fibrin molecule.
Plasminogen and tPA bind to lysine residues exposed by pro-
teolysis of fibrin by plasmin. Plasmin that is bound to fibrin is
relatively protected from inhibition by 𝛼
2
-antiplasmin bound
to fibrin by FXIIIa. A key inhibitor of tPA is plasminogen
activator inhibitor-1 (PAI-1). Additional fibrinolysis inhibitor,
thrombin activatable fibrinolysis inhibitor (TAFI), downreg-
ulates plasminogen activation by removing plasmin-binding
C-terminal lysine and arginine residues on fibrin [3].
Fibrin structure itself directly affects the rate of fibri-
nolysis, reflected by faster lysis of looser fiber networks
regardless of the fiber thickness, which might affect the
thrombotic risk [3, 6]. This effect of fibrin structure on lysis
is mediated both by differences in accessibility of the clot to
fibrinolytic proteins and differences in the binding of tPA and
plasminogen to clots with different structures [7].
2. Evaluation of Fibrin Clot Characteristics
Architecture of a fibrin clot can be characterized by (1)
the pore size typically estimated using clot permeability or
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permeation (Darcy’s constant, or 𝐾
𝑠
), a measure of clot
surface allowing flow through networks under different
hydrostatic pressures; (2) the lag phase by turbidimetry that
reflects the time to the start of lateral protofibril aggregation;
(3) maximum absorbance of a clot that reflects an average
fibrin fiber thickness. Clot turbidity is related to the number
of fibrin fibers, their thickness, the number of branching
points, and the uniformity of fiber distribution [8–10]. The
size of the pores in the fiber network or the density of clots
can be assessed visually on scanning electron microscopy
(SEM) or confocal microscopy images. The stiffness of fibrin
clots generated from purified fibrinogen, plasma, or whole
blood is evaluated using rheometry and its measure is the
maximum elastic storage modulus. Other parameters of the
clot including the fractal dimension reflecting its structural
complexity can also be calculated using this approach usually
in whole blood clots [11].
Since more than 30 years it has been proven that fibrin
networks composed of thinner, highly branchedfibers usually
are less permeable, more rigid, and less susceptible to lysis
[10, 12, 13].The so-called prothrombotic fibrin clot phenotype
involves faster formation of dense meshwork (reflected by
lower 𝐾
𝑠
values) composed of thinner and highly branched
fibers that are relatively resistant to plasmin-induced lysis.
Contrary, fibrin networks composed of thick fibers have
larger pores, which results in functional assays to increased
permeability and susceptibility to fibrinolysis [10, 12, 13].
Nowadays the most commonly used assay to assess
efficiency of fibrinolysis in patients is the measurement of
clot lysis time (CLT) developed by Lisman et al. [14] in 2001.
In this assay blood clotting is triggered by tissue factor (TF)
in the presence of phospholipid vesicles and fibrinolysis is
activated by addition of recombinant tPA together with TF
[12]. Other assays to test fibrinolytic capacity use varying tPA
concentrations with or without addition of thrombin before
or after fibrin gel formation.
Fibrin clot properties can be studied when thrombin or
other clotting activators are added to purified or recombinant
fibrinogens. However, assays in which clots are generated
from citrated plasma represent the most commonly used
approach in large groups of patients. Structural and func-
tional differences between plasma fibrin clots and thosemade
from purified fibrinogen have been well documented. For
example, fibrin network formed from citrated plasma is com-
posed of thicker fibers making looser meshwork compared
with that formed from purified fibrinogen [10, 12].
In summary, plasma fibrin clot permeability and clot
lysis are valuable measures of clot structure and function,
which can be used in evaluation of various diseases. However,
these methods are not standardized and large interlaboratory
differences are observed.
3. Modifiers of Fibrin Clot Properties
Experimental and clinical studies have identified a number of
modifiers of clot structure, both genetically and/or environ-
mentally determined, that in most cases are implicated—in
a direct or indirect manner—in the occurrence of the pro-
thrombotic fibrin clot phenotype (Figure 1).
Most of these factors are associated with increased risk
of venous thrombosis. A key regulator of fibrin structure is
the concentration of fibrinogen and its function. Variation
in fibrinogen concentrations explains only up to 18% of the
variation in clot permeability [15]. Other recognizedmodula-
tors of fibrin structure involve acute phase proteins including
C-reactive protein which rises together with fibrinogen in
several common diseases associated with elevated risk of
thrombosis (Figure 1).
It has been established that genetic factors explain 10–50%
of variance in fibrin clot measures [16]. About 25% of rare
congenital dysfibrinogenemias resulting from mutations in
all three fibrinogen genes, despite low levels of functional
fibrinogen measured using the Clauss assay, are linked with
VTE and at least some of them are known to significantly alter
fibrin clot structure [17]. The incomplete penetrance of the
thrombotic phenotype in some dysfibrinogenemic subjects
with the same genotype is highly suggestive of other genetic
or environmental confounders. A stronger impact on fibrin
clot characteristics could be related to common genetic poly-
morphisms largely in genes encoding three fibrinogen chains.
A common 𝛽-chain polymorphism, due to a substitution of
Lys with Arg at residue 448, has been shown to affect the
clot structure [18], but not all studies demonstrated it [19].
A𝛼 fibrinogen Thr312Ala polymorphism has been reported
to increase FXIIIa-catalyzed reactions and to lead to the
formation of thicker fibrin fibers [20]. A functional splice
variant of the 𝛾-chain, fibrinogen 𝛾󸀠, with 20 new residues
that contain binding sites for both thrombin and the FXIII
B-subunit is also linked with an unfavorable prothrombotic
clot phenotype [21]. Finally, FXIII Val34Leu significantly
alters fibrin structure resulting in the formation of a clot
with smaller pores and thinner fibers [22]. At high plasma
fibrinogen concentrations, the FXIII Leu34 variant showed a
protective effect through the formation of more permeable
fibrin clots that are more susceptible to lysis, while at low
fibrinogen concentration the effect was reversed, suggesting
that protection against thrombosis by FXIII 34Leu only
occurs in hyperfibrinogenemia [23]. Taken together, a role
of common genetic factors in fibrin properties appears to be
minor as compared to a broad spectrum of potent acquired
factors largely driven by their complex proinflammatory and
prothrombotic effects.
Wolberg et al. have shown that fibrin fibermass-to-length
ratio decreases with increasing prothrombin levels (above
100% of plasma levels), in a dose-dependent manner [24].
In both purified fibrinogen and plasma-based systems, clots
produced in the presence of high thrombin concentrations
are characterized by thin fibers that form a network with
small pores [25].
Lipoprotein(a) that contains apolipoprotein(a), apo(a),
with domains homologous with the kringle domains IV
and V of plasminogen, has been found to be associated
with lower clot permeability composed of thinner fibers
and impaired susceptibility to fibrinolysis [26]. Small apo(a)
isoforms are associated with abnormal clot characteristics
and hypofibrinolysis [26].
A number of common diseases, including those known
as the risk factors for thrombosis, have been demonstrated
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Figure 1: Factors thatmodify normal plasma fibrin clot phenotype to prothrombotic phenotype. A plasma fibrinogen concentration is amajor
determinant of clot properties. The larger fibrinogen concentrations, the denser fibrin networks. Alterations to fibrinogen function could be
genetically determined and acquired largely associated with posttranslational modifications, for example, glycation or homocysteinylation.
Environmental factors have a larger impact on clot phenotype and lysability, largely related to enhanced inflammation and thrombin
generation observed in several common chronic diseases, including cancer and rheumatic disorders that representwell-established risk factors
for venous thrombosis. COPD, chronic obstructive pulmonary disease; RA, rheumatoid arthritis; APS, antiphospholipid syndrome.
to deteriorate plasma fibrin clot phenotype by rendering
them denser and resistant to lysis (Figure 1). Mechanisms
underlying these associations are the consequence of post-
translational modifications such as oxidation, glycation, and
homocysteinylation (often combined like in diabetes) and
binding proteins to the fibrin fibers that can confound phys-
iological interactions, for instance, with proteins involved
in fibrinolysis [27–29]. The most common diseases related
to thrombosis are inflammatory by nature. Reduced clot
permeability and susceptibility to lysis have been observed
in rheumatoid arthritis [30], chronic obstructive pulmonary
disease [31], and inflammatory bowel disease [32]. Binding of
C-reactive protein (CRP) with fibrinogen and fibrin [33] is
likely to contribute to the prothrombotic clot phenotype as
evidenced by correlations of CRP with plasma clot perme-
ability and lysis [30–32].
4. Fibrin Clot Properties Assessed In Vitro in
Patients with VTE
Venous thromboembolism (VTE), including deep vein
thrombosis (DVT) and pulmonary embolism (PE), affects
1 to 3 per 1000 persons per year [34–36], which renders
this entity a common medical condition associated with
significant morbidity and mortality [37].
Growing evidence from multiple studies using vari-
ous plasma-based assays indicates that both DVT and PE
are associated with altered fibrin clot properties including
impaired fibrinolytic capacity [10, 12, 38, 39]. The most com-
pelling evidence for involvement of plasma fibrin clot char-
acteristics in the pathogenesis of VTE is indirect and comes
from several studies exploring efficiency of clot fibrinolysis.
Impaired clot lysability is in part related to abnormal clot
structure, which is commonly reflected by an inverse associa-
tion between𝐾
𝑠
and CLT reported in many disease states [10,
12]. Curnow et al. [40] showed that hypercoagulable patients
with arterial thrombosis or VTE, pregnancy complications,
or autoimmune diseases have increased fibrin generation and
reduced fibrinolysis. Hypofibrinolysis measured in plasma
using CLT values introduced by Lisman et al. [14] has been
shown in subjects following the first DVT episode [41]. An
increase in risk for DVT in patients with hypofibrinolysis and
a 2-fold increased risk of DVT in subjects with CLT above the
90th percentile have been observed [41]. 77% of variation in
CLT in venous thrombosis patients can be attributed to levels
of PAI-1, TAFI, prothrombin, and 𝛼
2
-antiplasmin, but not to
plasma fibrinogen [42].
Analysis of VTE patients demonstrated that three estab-
lished risk factors for VTE, namely, oral contraceptives,
immobilization, and the presence of FV Leiden, markedly
increase the risk associated with the longest CLT; hypofib-
rinolysis with these factors gives 20-, 10.3-, and 8.1-fold
increases in the VTE risk, respectively, compared with indi-
viduals with the shortest lysis time without the risk factors
[43].
In 2009 unfavorably altered plasma fibrin clot properties
were documented in patients with prior unprovoked VTE
[44]. After excluding known thrombophilia, cancer, trauma,
surgery, pregnancy, and other established risk factors, VTE
patients have been found to have lower plasma clot perme-
ability, higher maximum clot absorbance, and prolonged clot
lysis than controls free of thrombotic events, while similarly
unfavorable abnormalities were in relatives of VTE patients,
which indicates genetic background of abnormal fibrin clot
properties in VTE with no history of thrombotic events
[44]. This study might suggest that abnormal plasma fibrin
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characteristics represent novel risk factors for idiopathic
VTE. However, long-term cohort studies are needed to
validate this hypothesis. Higher maximum clot absorbance
usually inversely correlated with clot permeability is con-
sidered a marker of thicker fibers [8]. However in contrast
to many in vitro studies in which clots composed of thin-
ner fibers are more resistant to fibrinolysis, plasma clots
from real patients with thrombotic manifestations can be
composed of fibers with a similar or larger thickness as
compared to the control subjects, but they are less permeable
and poorly lysable. Patients following VTE represent such
individuals, which suggests that plasma clots possess a far
more complex structure in terms of its functional consequen-
ces.
Traby et al. [45] have reported that there is a weak asso-
ciation between CLT and risk of VTE recurrence only in
women, who experienced a first unprovoked VTE without
cancer or thrombophilia and were followed for an average of
46 months after anticoagulation withdrawal.
Using a global assay of fibrinolysis that tested the patient’s
blood fibrinolytic capacity by application of the euglobulin
fraction of plasma to a preformed clot of plasminogen-rich
bovine fibrin, Skov et al. [46] demonstrated that fibrino-
lytic capacity is impaired in VTE patients below 50 years
compared with young stroke survivors and this difference
remained significant after adjustment for multiple con-
founders including PAI-1.
A history of provoked and unprovoked DVT episodes
has been later shown to be associated with unfavorable fibrin
plasma clot properties [47]. It remains to be established
whether unfavorable plasma fibrin clot phenotype may pre-
dispose to provoked DVT.
We have demonstrated that residual vein obstruction
following DVT is linked with faster formation of denser
plasma fibrin clots displaying impaired lysability [48]. These
patients had 14% lower clot permeability and 11% longer
lysis time, with no differences related to thrombophilia and
duration or stability of anticoagulant therapy [48].
It remains unclear whether plasma fibrin clot features
could predict recurrent VTE episodes. Regarding fibrinolytic
parameters, in a two-centre case-control study performed in
English and Dutch patients, hypofibrinolysis, defined as CLT
values (at 3 months after discontinuation of the anticoagu-
lant therapy) above the 90th percentile calculated in control
subjects (>122min), was associated with a 1.8-fold increased
risk of a first VTE, while in the follow-up study the rela-
tionship between a recurrent VTE and hypofibrinolysis was
estimated as weak (hazard ratio 1.5, 𝑝 > 0.05) [49]. A prog-
nostic value of plasma fibrin clot phenotype following DVT
alone has been shown recently [50]. We have observed that
subjects with recurrent DVT during follow-up were cha-
racterized by slightly lower plasma clot permeability and 15%
longer CLTmeasured at 3 months since the index event com-
pared with the remainder (Figure 2) [50].
Regarding PE, Martinez et al. have reported that clots
made from plasma of patients with acute isolated PE were
characterized by faster CLT and lower fiber density when
comparedwithDVT alone [4]. Absent perfusion in some seg-
ments of the pulmonary arteries (perfusion defects) following
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Figure 2: Recurrent VTE episodes during follow-up in relation
to plasma fibrin clot properties measured after 3–6 months since
the index event (based on [4, 5]). Lower clot permeability and
prolonged clot lysis have been reported in patients who experienced
VTE recurrences after anticoagulation withdrawal, with a larger
impact on deep vein thrombosis. Data are shown as difference
between means and confidence interval ranges in %. VTE, venous
thromboembolism; DVT, deep vein thrombosis; PE, pulmonary
embolism; 𝐾
𝑠
, fibrin clot permeability coefficient; CLT, fibrin clot
lysis time.
PE detected on angiography has been shown to be associated
with impaired fibrinolysis [51].
We have demonstrated recently the association of plasma
clot properties and the risk of PE recurrence during a 4-
year follow-up [52].These associations were observed in sub-
jects who discontinued anticoagulant therapy after the first
episode of provoked or unprovoked PE (Figure 2). It is pos-
sible that screening for the prothrombotic plasma fibrin clot
phenotype together with plasmaD-dimer and thrombin gen-
erationmay help identify patients at high risk of recurrent PE.
Analysis of thrombotic material removed from the right
atrium and pulmonary (lobar and segmental) arteries of
a patient with acute severe PE who underwent surgical
embolectomy showed that distally located thrombi contain
more densely packed fibrin fibers compared with the proxi-
mal thrombi from the lobar pulmonary arteries and the right
atrial thrombus [5]. It indicates that abnormal fibrin is present
in thrombi retrieved from patients with DVT and the sub-
sequent PE.
In summary, DVT and/or PE are associated with the pro-
thrombotic plasma fibrin clot phenotype especially reduced
clot permeability and lysability, and these features might have
a prognostic value both in the prediction of first and recurrent
episodes.
5. Venous Thrombosis at Unusual Location
Studies on clot properties in patients who developed throm-
bosis at unusual location suggest that prothrombotic plasma
clot phenotype contributes to such thromboembolic events,
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indicating that venous thrombosis is associated with certain
common fibrin characteristics and the location of the event is
largely driven by anatomical peculiarities or abnormalities.
The Budd-Chiari syndrome is a rare disorder caused by
obstruction of the hepatic outflow tract, and its classic form
involves thrombosis of one of the hepatic veins. This disease
has been shown to be linked to less efficient fibrinolysis in
part associatedwith elevated PAI-1 activity, but not with TAFI
[53]. Marked differences in clot lysis between Chinese and
European patients with this syndrome have been reported
[54]. Data on clot architecture in this syndrome have not been
published, but based on a significant inverse association of
CLT with plasma clot permeability observed in most studies,
itmight expected that denser fibrin networks assessed in vitro
are formed at least in some patients with this disease.
Cerebral sinus venous thrombosis (CSVT) is a rare
disorder. Its recurrent episodes have been observed more
frequently in patients with unfavorable clot phenotype; CVST
was associated with 21% higher baseline fibrinogen, 20%
lower plasma clot permeability and 17% greater fibrin mass
within a clot [55]. Altered fibrin clot properties similar
to those found following CVST have also been reported
in patients who experienced retinal vein occlusion [56].
Prolonged lysis time associated with increased endogenous
thrombotic potential following retinal vein thrombosis has
been confirmed by Italian investigators [57].
In summary, prior thrombosis at unusual locationmay be
linked to the prothrombotic plasma fibrin clot phenotype.
6. Inherited and Acquired Thrombophilia
It is estimated that genetic factors are responsible for up
to 25% of unprovoked VTE [58]. Factor V Leiden is the
most common inherited thrombophilia that occurs in 5% of
Europeans. A heterozygous form of FV Leiden, perceived as a
mild thrombophilic defect, has been reported to be associated
with impaired efficiency of lysis in apparently healthy women
below 50 years, which is independently predicted by the TAFI
activity, and it has no significant effect on the fibrin network
structure, reflected by clot permeability [59]. The FV Leiden
paradox, that is, a relatively lower PE risk comparedwith high
DVT risk in carriers, has not been elucidated [60]. Until now
no evident fibrin clot-relatedmechanisms have been reported
as a potential explanation of this paradox.
The G20210A prothrombin mutation is the second most
common inherited abnormality that is found in 4.6–8% of
patients after VTE and in 0.7–2.6% of the general white
population [58]. The G20210A mutation carriers have about
20–25% higher prothrombin levels than noncarriers. Anal-
ysis of 32 carriers versus 30 noncarriers showed impaired
fibrinolysis reflected by 14.5% longer CLT but this difference
disappeared after TAFI inhibition [61]. They also confirmed
that addition of prothrombin to normal plasma to raise
prothrombin level to 125% and 150% results in longer CLT
[61]. Our data indicated that also clot permeability is reduced
in the G20210A prothrombin mutation carriers (A. Undas,
unpublished data).
Genetically determined deficiencies of natural anticoagu-
lants, that is, antithrombin, protein C, and protein S, increase
the risk of a first VTE by at least 10-fold and are observed
in <0.5% of the general white population with the incidence
up to 5% among subjects with unprovoked VTE [58]. It is
unclear whether such abnormalities alter fibrin clot prop-
erties. Reduced clot permeability and lysability have been
reported in a single patient with antithrombin deficiency
with normalization of clot permeability upon addition of
antithrombin to plasma [62].
Antiphospholipid syndrome (APS) is a systemic autoim-
mune disease associated with thrombotic complications,
including VTE, in the setting of detectable antiphospho-
lipid antibodies [63, 64]. APS patients were characterized
by higher maximum plasma clot absorbency, lower clot
permeability, shorter lag phase, prolonged clot lysis time,
lower maximum rate, and higher maximum level of D-dimer
released from clots, also after adjustment for fibrinogen, body
mass index (BMI), and smoking status [65]. There were no
differences in plasma fibrin clot characteristics between pri-
mary and secondary APS. Patients with “double” or “triple”
antibody positivity had less permeable plasma clots compared
with those with one positive antibody, with no difference in
clot lysis. Patients who experienced PE formed plasma fibrin
clots of higher permeability and lysability than those with
DVT alone. Clots generated from plasma of APS patients
who experienced stroke and/or myocardial infarction were
less permeable and were lysed slower compared with those
with VTE alone [65]. This study is the first to show that APS
is associated with prothrombotic plasma fibrin clot pheno-
type, with worse characteristics in patients following arterial
thrombosis. Low clot permeability in APS was confirmed by
Vikerfors et al. [66] andmoreover, prolonged fibrinolysis was
observed in particular in APS patients with previous arterial
thrombosis. A role of microparticles in abnormal clot struc-
ture in APS patients has also been suggested [66]. Prothrom-
botic plasma clot properties in young or middle aged APS
subjects following thrombotic events have been shown to be
linked to progression of atherosclerosis measured in carotid
arteries, which highlights again associations between fibrin-
mediated mechanisms observed in both atherosclerosis and
thrombosis [67].
In summary, there is evidence that most inherited throm-
bophilias and APS are associated with unfavorable plasma
fibrin clot properties, whichmight contribute to their throm-
boembolic clinical manifestations.
7. Complications of VTE
Chronic thromboembolic pulmonary hypertension (CTEPH)
is a severe complication that occurs in 1–4% of patients
following PE. It has been reported that fibrin clots made from
fibrinogen purified from patients with CTEPH are in part
resistant to plasmin-mediated lysis as compared to healthy
individuals [68]. This observation suggests that structural
or functional abnormalities in fibrinogen molecules and
the subsequent fibrin properties may be involved in the
development of CTEPH by prolonged fibrin clot presence
within the pulmonary arteries and stimulation of remod-
eling of the thrombi into fibrotic intravascular material.
Interestingly, analysis of purified fibrinogen and fibrinogen
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gene sequencing of patients with CTEPH showed a relatively
high incidence of inherited dysfibrinogenemias in which
abnormal fibrin clot structure and lysis were described [69].
Moreover, it has been reported that patients with these
CTEPH-associated dysfibrinogenemias have low clot tur-
bidity, decreased porosity, and fibrinolytic resistance, along
with disorganized fibrin networks composed of thinner fibers
and more extensive fiber branching [70]. Since abnormal
clot architecture and fibrinolytic resistance may contribute
to incomplete clot resolution in this form of CTEPH, clot
properties may help identify patients at risk of this compli-
cation. Given increased therapeutic options in CTEPH and
their benefits [71, 72], efficacy of the therapy can also be in
part determined by fibrin clot characteristics.
The most common complication of DVT is the post-
thrombotic syndrome (PTS) observed in 20–50% of patients
within the first 1-2 years after the index event [73]. Patients
who developed PTS suffer from light pain, occasional
swelling, and venous ectasia, but with time they complain of
chronic pain, tough edema, skin induration, and leg ulcer,
which decrease the quality of life. The pathophysiology of
PTS is not fully understood, butmost investigators highlight a
key role of systemic inflammation with the subsequent tissue
remodeling and fibrosis [74]. Recently we have demonstrated
that prothrombotic plasma clot phenotype, in particular
lower clot permeability determined 3 months since the index
event, predisposes to PTS [50]. Severe PTS was associated
with more unfavorable clot variables, including almost 20%
lower plasma clot permeability [50]. The Villalta scale, a
measure of the severity of PTS, showed associations with clot
permeability and lysability.We provided evidence that denser
plasma fibrin clot formation and their impaired lysis may
allow identifying patients following DVT who are likely to
develop PTS.
8. Antithrombotic Agents and Fibrin
Clot Properties
Anticoagulation is the primary approach to therapy of VTE.
Heparins are commonly used as the first-line therapy in
acute VTE, especially in cancer-associated episodes [75].The
current guidelines recommend lifelong anticoagulation for
patients after a second unprovoked VTE and inmost subjects
after first episodes [36]. Vitamin K antagonists (VKA) have
been the standard of care in VTE for 60 years. Nonvitamin
K oral antagonists (NOACs) have shown similar efficacy and
improved safety profile when compared to warfarin in VTE
and they are now used worldwide [36].
It is easy to foresee that all anticoagulant agents that
decrease thrombin generation and consequently fibrin for-
mation may improve plasma fibrin clot properties. Unfrac-
tionated and low-molecular-weight heparins have been
shown to improve clot properties as evidenced by analysis of
nanostructure of fibrin clots in the absence of antithrombin
[76].
Warfarin administration when International Normalized
Ratio is in the range of 2-3 increased plasma fibrin clot
permeability by 28–50% compared with the control clots
[77]. Similar increases in clot permeability can be observed
at therapeutic plasma concentrations of fondaparinux and
apixaban (by 58–76% and 36–53%, resp.) [78]. Looser clot
structure has also been shown in the presence of argatroban,
bivalirudin, lepirudin, and danaparoid [79].
Rivaroxaban can improve clot properties as evidenced by
formation of clots composed of thicker fibrin fibers and larger
pores with 2-fold increased clot permeability and 3-fold faster
lysis comparedwith the control clots generated in the absence
of rivaroxaban [80]. Similar improvement in the presence
of rivaroxaban has been reported in whole blood clots
[81]. Direct thrombin inhibitors have been demonstrated to
increase clot susceptibility to lysis and this effect was in
part mediated by TAFI [82]. Reduced thrombin formation
and suppressed thrombin-mediated reactions during NOAC
treatment appear to account for the formation of less compact
and more lysable fibrin clots. Whether the extent of changes
in fibrin clots contributes to bleeding risk in VTE remains to
be explored.
Low-dose aspirin has also been found to increase clot
permeability and susceptibility to lysis, as demonstrated in
clots generated from human plasma, purified fibrinogen and
in cellular system [83, 84]. Acetylation of fibrinogenmolecule
is considered a major mechanism underlying this effect [83].
It is unclear whether these actions of aspirin contribute to its
clinical outcomes observed also in secondary prevention of
VTE.
Statins, a potent cholesterol-lowering class of drugs pro-
ducing multiple antithrombotic actions which is increasingly
used for other indications, have also been reported to increase
clot permeability and lysability with no association with
reduced cholesterol levels [85, 86]. It has been postulated that
modulation of fibrin clot structure and function represents
an additional beneficial effect of this widely usedmedications
that have been shown to reduce the risk of VTE [87].
In summary, VKA, NOAC, and other anticoagulant
agents favorably alter plasma fibrin clot properties. Less pro-
nounced beneficial fibrin-related effects produce statins and
aspirin, and these effects can be detected in vitro. Clinical
relevance of these effects is unknown.
9. Concluding Remarks
The so-called prothrombotic characteristics of a fibrin clot,
including dense fiber networks displaying reduced plasmin-
induced lysability measured in vitro in plasma, are con-
sidered a potential novel risk factor for VTE like MI or
ischemic stroke. Observational studies have demonstrated
that altered plasma clot phenotype, in particular low clot
permeability and CLT, characterize patients following VTE
and thrombosis at unusual sites as well as those who expe-
rienced recurrent VTE or PE during follow-up. The precise
molecular mechanisms underlying this association are still
poorly understood and involve genetic and acquired factors
with a major contribution of increased thrombin generation
and inflammation. Of note, plasma fibrin networks are
favorably modulated in subjects receiving not only various
anticoagulant agents, but also aspirin or statins, which might
contribute to beneficial effects of these medications in terms
of prevention of VTE.
BioMed Research International 7
It remains to be established to what extent unfavorable
fibrin clot properties affect the risk of first or recurrent
DVT and PE. Further large prospective studies are needed to
evaluate a prognostic value of fibrin clot measures in a broad
spectrum of venous thromboembolic disorders.
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